Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SELL | P14151 | 2/20 | 0.53 |
| ▸ | SELP | P16109 | 2/20 | 0.53 |
| ▸ | SELE | P16581 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20236673 | 0.83 | KMT2A (0.58) | KMT2ANR1H4EPHX2ALDH1A1SELL | |
| SCHEMBL1134867 | 0.83 | TSHR (0.60) | KMT2ATSHRALDH1A1MEN1 | |
| SCHEMBL4508687 | 0.81 | TSHR (0.63) | KMT2ATSHRNR1H4EPHX2ALDH1A1 | |
| SCHEMBL16994790 | 0.81 | TSHR (0.63) | KMT2ATSHRALDH1A1MEN1 | |
| SCHEMBL27720379 | 0.80 | NR1H4 (0.58) | KMT2ANR1H4MEN1 | |
| SCHEMBL5374862 | 0.79 | KMT2A (1.00) | KMT2ATSHRNR1H4EPHX2ALDH1A1 | |
| SCHEMBL7314826 | 0.79 | KMT2A (0.71) | KMT2ATSHRNR1H4EPHX2ALDH1A1 | |
| SCHEMBL3503996 | 0.78 | ALDH1A1 (0.81) | KMT2ATSHRNR1H4EPHX2ALDH1A1 | |
| SCHEMBL10936984 | 0.77 | ALDH1A1 (0.59) | KMT2ATSHRNR1H4EPHX2ALDH1A1 | |
| SCHEMBL4402768 | 0.77 | EPHX2 (0.66) | KMT2ATSHRNR1H4EPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101484442-A | Compounds that are agonists of muscarinic receptors and tha may be effective in treating pain, alzheimer's disease and/or schizophrenia | ASTRAZENECA AB (SE) | 2009-07-15 | — | — | CN | disclosed |
| EP-2024359-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DECEASE AND/OR SCHIZOPHRENIA | AstraZeneca AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007126362-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007126362-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | KMT2A 3736/4885TSHR 1580/4885NR1H4 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.